Jean Abraham
A5007341153- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Radiomics and Machine Learning in Medical Imaging
- Bioinformatics and Genomic Networks
- Estrogen and related hormone effects
- Computational Drug Discovery Methods
- Advanced NMR Techniques and Applications
- AI in cancer detection
- Advanced Breast Cancer Therapies
- PARP inhibition in cancer therapy
- Genetic factors in colorectal cancer
- Medical Imaging Techniques and Applications
- Economic and Financial Impacts of Cancer
- Inflammatory mediators and NSAID effects
- Breast Lesions and Carcinomas
- DNA Repair Mechanisms
- Atomic and Subatomic Physics Research
- Global Cancer Incidence and Screening
- Cancer Cells and Metastasis
- Plant-based Medicinal Research
- Advanced MRI Techniques and Applications
- Gene expression and cancer classification
University of Cambridge
2016-2025
Cambridge University Hospitals NHS Foundation Trust
2015-2024
Cancer Research UK Cambridge Center
2013-2024
Addenbrooke's Hospital
2003-2023
Cancer Research UK
2009-2022
Institute for Advanced Study
2022
University of Miami
2022
Wake Forest University
2022
NIHR Cambridge Biomedical Research Centre
2013-2021
National Health Service
2019-2020
Breast cancers are complex ecosystems of malignant cells and the tumour microenvironment
BackgroundPrevious studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate relationship RCB with long-term prognosis across different phenotypic subtypes breast cancer, assess generalisability broad range practice settings.MethodsIn this analysis, 12 institutes and trials Europe USA were identified by personal communications...
BackgroundAdjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant non-inferior the 12-month regarding disease-free survival.MethodsThis study an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in UK. randomly assigned cancer,...
Our purpose is to investigate the feasibility of imaging tumor metabolism in breast cancer patients using 13 C magnetic resonance spectroscopic (MRSI) hyperpolarized label exchange between injected [1- C]pyruvate and endogenous lactate pool. Treatment-naïve were recruited: four triple-negative grade 3 cancers; two invasive ductal carcinomas that estrogen progesterone receptor-positive (ER/PR+) HER2/neu-negative (HER2−), one 2 3; ER/PR+ HER2− lobular carcinoma (ILC). Dynamic MRSI was...
Integration of variant reads across patient-specific mutation loci enables sensitive ctDNA quantification in plasma cell-free DNA sequencing data.
The increasing trend for incorporation of biological sample collection within clinical trials requires procedures which are convenient and acceptable both patients clinicians. This study investigated the feasibility using saliva-extracted DNA in comparison to blood-derived DNA, across two genotyping platforms: Applied Biosystems Taqman™ Illumina Beadchip™ genome-wide arrays.Patients were recruited from Pharmacogenetics Breast Cancer Chemotherapy (PGSNPS) study. Paired blood saliva samples...
The ARTemis trial was developed to assess the efficacy and safety of adding bevacizumab standard neoadjuvant chemotherapy in HER2-negative early breast cancer.
Anthracyclines and taxanes have been the standard neoadjuvant chemotherapies for breast cancer in past decade. We aimed to assess safety efficacy of addition gemcitabine accelerated paclitaxel with epirubicin cyclophosphamide, also effect sequencing blocks cyclophosphamide (with or without gemcitabine).
Mainstreaming genetic medicine, increased media coverage and clinical trials for BRCA mutation carriers are leading oncologists into more patient discussions about testing. variants of uncertain significance (VUS) occur in 10–20 % tests. VUS detection introduces additional uncertainty potentially clinician. We aimed to explore the ability breast cancer specialists (BCS) UK correctly respond a report. A survey sent 800 BCS collected demographics data, general knowledge interpretation...
Associations between taxane-related sensory neuropathy (TRSN) and single-nucleotide polymorphisms (SNP) have previously been reported, but few replicated in large, independent validation studies. This study evaluates the association investigated SNPs TRSN, using genotype data from a of chemotherapy-related toxicity patients with breast cancer.
PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer
Abstract Introduction Tamoxifen is one of the most effective adjuvant breast cancer therapies available. Its metabolism involves phase I enzyme, cytochrome P4502D6 (CYP2D6), encoded by highly polymorphic CYP2D6 gene. variants resulting in poor tamoxifen are hypothesised to reduce its efficacy. An FDA-approved pre-treatment gene testing assay However, evidence from published studies evaluating as predictive factors efficacy and clinical outcome conflicting, querying utility testing. We...
There is a need to improve prediction of response chemotherapy in breast cancer order clinical management and this may be achieved by harnessing computational metrics tissue pathology. We investigated the association between quantitative image derived from analysis digital pathology slides women with who received neoadjuvant chemotherapy. digitised sections both diagnostic surgical samples tumours 768 patients enrolled Neo-tAnGo randomized controlled trial. subjected images systematic...
506 Background: Adjuvant trastuzumab has significantly improved outcomes for HER2+ EBC pts, using the 12m duration empirically adopted from pivotal registration trials. A shorter could reduce toxicities and cost whilst providing similar efficacy. No reduced-duration trial to date demonstrated non-inferiority. Methods: PERSEPHONE is a randomised phase 3 non-inferiority comparing 6 trastuzumab, largest internationally. Mapping onto standard UK practice, all pts were eligible. Stratification by...
Abstract Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect minimal residual disease has been an area increasing interest. Multiple methods have proposed but few studies compared the performance different approaches. Here, we compare detection ctDNA in serial plasma samples from patients with breast using tumor‐informed tumor‐naïve assays designed structural variants (SVs), single nucleotide (SNVs), and/or somatic copy‐number aberrations, by multiplex PCR, hybrid...
There is increasing evidence that elevated body mass index (BMI) associated with reduced survival for women breast cancer. However, the underlying reasons remain unclear. We conducted a Mendelian randomization analysis to investigate possible causal role of BMI in from
Purpose To compare hyperpolarized carbon 13 (13C) MRI with dynamic contrast material–enhanced (DCE) in the detection of early treatment response breast cancer. Materials and Methods In this institutional review board–approved prospective study, a woman triple-negative cancer (age, 49 years) underwent 13C after injection [1–carbon {13C}]-pyruvate DCE at 3 T baseline one cycle neoadjuvant therapy. The 13C-labeled lactate-to-pyruvate ratio derived from pharmacokinetic parameters transfer...
<p>Supplementary Figures 1-20</p>
<div>Abstract<p>The intertumor and intratumor heterogeneity of triple-negative breast cancers, which is reflected in diverse drug responses, interplays with tumor evolution. In this study, we developed a preclinical experimental analytical framework using patient-derived xenografts (PDTX) from patients treatment-naïve cancers to test their predictive value personalized cancer treatment approaches. Patients matched PDTXs exhibited concordant responses neoadjuvant therapy two trial...